PODD

Insulet Corporation develops, manufactures, and markets the Omnipod platform, a tubeless insulin management system for people with insulin-dependent diabetes. Headquartered in Acton, Massachusetts, the company operates manufacturing facilities in the United States and China, serving customers across North America, Europe, and select international markets. The Omnipod System consists of a disposable Pod that delivers insulin continuously for up to three days and a handheld Personal Diabetes Manager or smartphone app for wireless control. The company's flagship product, Omnipod 5, is the first tubeless automated insulin delivery system cleared by the FDA, featuring integration with Dexcom continuous glucose monitoring technology. Insulet also offers Omnipod DASH, a second-generation platform with Bluetooth connectivity and smartphone control. The company employs approximately 3,000 people and generates annual revenue exceeding $1.5 billion as of recent fiscal periods. Insulet maintains strategic partnerships with major diabetes technology companies and pharmacy benefit managers to expand market access. Recent developments include international expansion of Omnipod 5, the acquisition of certain assets to enhance its manufacturing capabilities, and ongoing clinical studies to support additional automated insulin delivery features. The company focuses exclusively on diabetes care, differentiating itself through its proprietary tubeless pump technology that eliminates the tubing required by traditional insulin pumps.